United States was Zoetis’s largest segment in fiscal 2025, bringing in $5.10B of $9.35B (55%).
| Segment | FY 2011 | FY 2012 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | — | — | ||||||||
| United States | $4.31B | $4.56B | $5.07B | $5.10B | ||||||||
| International | $3.68B | $3.91B | $4.10B | $4.25B | ||||||||
| Other Business Activities | — | — | — | — | ||||||||
| Total | $7.99B | $8.47B | $9.18B | $9.35B |
Zoetis brought in $9.35B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 1.9% from $9.18B in fiscal 2024. United States was the largest at $5.10B (54.5%), ahead of International at $4.25B (45.5%).
Compared with fiscal 2024, International grew 3.7% to $4.25B and United States grew 0.5% to $5.10B. From fiscal 2022 to 2025, combined revenue from these segments grew from $7.99B to $9.35B, a compound annual growth rate of 5.4%. United States' share of the total rose from 54.0% to 54.5%.
Cattle was Zoetis’s largest revenue line in fiscal 2014, bringing in $1.75B of $4.79B (37%).
| Products and Services | FY 2011 | FY 2012 | FY 2013 | FY 2014 |
|---|---|---|---|---|
| Cattle | — | — | $1.63B | $1.75B |
| Dogs & Cats | $1.29B | $1.33B | $1.41B | $1.45B |
| Vaccines | $1.08B | — | — | — |
| Other Pharmaceuticals | $724.00M | $710.00M | — | — |
| Parasiticides | — | $675.00M | — | — |
| Swine | — | $592.00M | $652.00M | $695.00M |
| Poultry | $501.00M | $506.00M | $551.00M | $568.00M |
| Medicated Feed Additives | $347.00M | $403.00M | — | — |
| Horses | $168.00M | — | $179.00M | $182.00M |
| Other Non-Pharmaceuticals | $129.00M | — | — | — |
| Other | — | — | — | $93.00M |
| Other (Fish & Sheep) | — | $94.00M | $85.00M | — |
| Contract Manufacturing | — | $28.00M | $53.00M | $50.00M |
| Total | $4.23B | $4.34B | $4.56B | $4.79B |
Zoetis brought in $4.79B from its seven revenue lines in fiscal 2014, the year ended December 31, 2014. Zoetis regrouped these revenue lines after fiscal 2013, so the total does not compare directly with that year's $4.56B. Cattle was the largest at $1.75B (36.5%), ahead of Dogs & Cats at $1.45B (30.3%) and Swine at $695.00M (14.5%). The other four revenue lines brought in $893.00M combined.
Compared with fiscal 2013, Cattle grew fastest, up 7.3% to $1.75B. Every revenue line above 2% of revenue grew.
Zoetis began breaking out Cattle in fiscal 2013, Swine in fiscal 2012, Other in fiscal 2014 and Contract Manufacturing in fiscal 2012. Zoetis stopped reporting Vaccines ($1.08B in fiscal 2011), Other Pharmaceuticals ($710.00M in fiscal 2012), Parasiticides ($675.00M in fiscal 2012) and three others as separate revenue lines.
United States was Zoetis’s largest region in fiscal 2017, bringing in $2.62B of $5.26B (50%).
| Geography | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|
| International | $2.68B | — | — | |||
| United States | $2.06B | $2.45B | $2.62B | |||
| United States (U.S.) | — | — | — | |||
| Europe, Africa, & Middle East (Euafme) | — | — | — | |||
| Canada & Latin America (Clar) | — | — | — | |||
| Asia Pacific (Apac) | — | — | — | |||
| Other Emerging Markets | — | $607.00M | $657.00M | |||
| Other Developed Markets | — | $302.00M | $339.00M | |||
| Brazil | — | $245.00M | $300.00M | |||
| Canada | — | $173.00M | $184.00M | |||
| Australia | — | $157.00M | $176.00M | |||
| China | — | $145.00M | $174.00M | |||
| United Kingdom | — | $151.00M | $149.00M | |||
| Japan | — | $127.00M | $138.00M | |||
| Germany | — | $125.00M | $137.00M | |||
| France | — | $117.00M | $121.00M | |||
| Spain | — | $82.00M | $93.00M | |||
| Italy | — | $83.00M | $89.00M | |||
| Mexico | — | $76.00M | $86.00M | |||
| Total | $4.74B | $4.84B | $5.26B |
Zoetis brought in $5.26B from its 14 regions in fiscal 2017, the year ended December 31, 2017. That was up 8.8% from $4.84B in fiscal 2016. United States was the largest at $2.62B (49.8%), ahead of Other Emerging Markets at $657.00M (12.5%) and Other Developed Markets at $339.00M (6.4%). The other 11 regions brought in $1.65B combined.
Compared with fiscal 2016, Brazil grew fastest, up 22.4% to $300.00M, while United Kingdom fell the most, down 1.3% to $149.00M.
Zoetis began breaking out Other Emerging Markets in fiscal 2016, Other Developed Markets in fiscal 2016, Brazil in fiscal 2016 and Canada in fiscal 2016. Zoetis stopped reporting International as a separate region after fiscal 2014, when it brought in $2.68B.
Zoetis (ZTS) reports its revenue by segment, by products and services and by geography. In fiscal 2025, United States was its largest segment, bringing in $5.10B (54.5% of the total), followed by International at $4.25B (45.5%).
United States was Zoetis' largest segment in fiscal 2025, bringing in $5.10B, or 54.5% of the $9.35B total across its two segments.
Cattle was Zoetis' largest revenue line in fiscal 2014, bringing in $1.75B, or 36.5% of the $4.79B total across its seven revenue lines.
United States was Zoetis' largest region in fiscal 2017, bringing in $2.62B, or 49.8% of the $5.26B total across its 14 regions.
International grew faster than United States in fiscal 2025, up 3.7% from $4.10B to $4.25B. United States grew 0.5% to $5.10B.
Every figure comes from Zoetis' annual financial filings, as reported. Each line keeps the name Zoetis gives it, and years follow its fiscal calendar.
Zoetis' revenue by segment goes back to fiscal 2011, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.